Advertisement

Topics

Epoetin Alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy

2014-08-27 03:54:05 | BioPortfolio

Summary

RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with non-myeloid cancer.

PURPOSE: This clinical trial is studying how well epoetin alfa works in treating cancer-related anemia in patients with non-myeloid cancer who are not currently receiving chemotherapy or radiation therapy.

Description

OBJECTIVES:

Primary

- Determine the efficacy of epoetin alfa, in terms of hematologic response, in patients with non-myeloid malignancy and cancer-related anemia who are not currently receiving chemotherapy or radiotherapy.

Secondary

- Determine time to hematologic response in patients treated with this drug.

- Determine transfusion requirements in patients treated with this drug.

- Determine the safety and tolerability of this drug in these patients.

- Determine the quality of life of patients treated with this drug.

OUTLINE: This is an open-label, nonrandomized, pilot, multicenter study.

Patients receive epoetin alfa subcutaneously on day 1 of weeks 1, 3, 5, 7, 9, and 11 in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline and then at weeks 5, 9, 13, and 17.

Patients are followed for 4 weeks.

PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.

Study Design

Masking: Open Label, Primary Purpose: Supportive Care

Conditions

Anemia

Intervention

epoetin alfa

Location

Jonsson Comprehensive Cancer Center, UCLA
Los Angeles
California
United States
90095-6996

Status

Active, not recruiting

Source

National Cancer Institute (NCI)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:54:05-0400

Clinical Trials [1153 Associated Clinical Trials listed on BioPortfolio]

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

The purpose of this study is to demonstrate that once every-2-weeks and once every-4-weeks treatment with epoetin alfa, a drug that increases red blood cell production, in patients with an...

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with solid tumors. It is not yet known whether epoetin alfa given once a week is more effective...

The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma

The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa versus placebo in reducing the transfusion requirements in anemic patients with multiple myeloma, and ...

Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

The purpose of this study is to evaluate the cost-effectiveness of epoetin alfa compared with darbepoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer. Epoe...

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with cancer who are receiving chemotherapy. It is not yet known whether epoetin alfa is more ef...

PubMed Articles [510 Associated PubMed Articles listed on BioPortfolio]

A strategy to reduce inflammation and anemia treatment's related costs in dialysis patients.

This is a post-hoc analysis evaluating erythropoiesis stimulating agents' (ESA) related costs while using an additional ultrafilter (Estorclean PLUS) to produce ultrapure dialysis water located within...

Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease.

Epoetin beta pegol (continuous erythropoietin receptor activator; C.E.R.A.) is currently widely used for the treatment of anemia associated with chronic kidney disease (CKD). Therapeutic control of an...

Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.

Anemia is an inevitable complication of hemodialysis, and the primary cause is erythropoietin deficiency. After diagnosis, treatment begins with an erythropoiesis-stimulating agent (ESA). However, som...

Structure-Function Relationships for Recombinant Erythropoietins: A Case Study From a Proposed Manufacturing Change With Implications for Erythropoietin Biosimilar Study Designs.

Comparability studies used to assess a proposed manufacturing change for a biological product include sensitive analytical studies to confirm there are no significant differences in structural or func...

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

Biosimilars are biological medicines that are approved via stringently defined regulatory pathways on the basis that comparable safety, efficacy, and quality have been demonstrated to their reference ...

Medical and Biotech [MESH] Definitions

This recombinant erythropoietin, a 165-amino acid glycoprotein (about 62% protein and 38% carbohydrate), regulates red blood cell production. Epoetin alfa is produced by Chinese hamster ovary cells into which the human erythropoietin gene has been inserted. (USP Dictionary of USAN and International Drug Names, 1996).

A recombinant protein which stimulates ERYTHROPOIESIS used to treat ANEMIA.

A recombinant alfa interferon consisting of 165 amino acids with arginine at positions 23 and 34. It is used extensively as an antiviral and antineoplastic agent.

A recombinant alfa interferon consisting of 165 amino acids with lysine at position 23 and histidine at position 34. It is used extensively as an antiviral and antineoplastic agent.

A recombinant alfa interferon consisting of 165 amino acid residues with arginine in position 23 and histidine in position 34. It is used extensively as an antiviral and antineoplastic agent.

More From BioPortfolio on "Epoetin Alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...


Searches Linking to this Trial